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Background: Recent lines of evidence suggest that prolactin (PRL) as a neurohormone may play a role in the activity of psoriasis and
some other immune-mediated diseases. Our aim was to evaluate the correlation between serum PRL levels and severity of psoriasis, viti-
ligo and alopecia areata.
Patients and methods: We performed a case–control study on 100 subjects: 75 patients; suﬀering from psoriasis, vitiligo and alopecia
areata; 25 patients in each group and 25 age- and sex-matched healthy controls.
Results: Serum prolactin levels were signiﬁcantly high in all three dermatological diseases in comparison with the control group
(P = 0.000). The mean ± SD of the serum prolactin levels was 21.8 ± 11.5 ng/ml, 16.9 ± 6.8 ng/ml, and 16.6 ± 8.0 ng/ml in patients with
alopecia areata, psoriasis and vitiligo respectively. Moreover, the serum prolactin levels in patients with alopecia areata and psoriasis
were signiﬁcantly correlated with disease severity (P < 0.05), however no statistically signiﬁcant correlation was noted between vitiligo
severity and serum prolactin levels (P > 0.05).
Conclusions: Prolactin may play a role in the pathogenesis of alopecia areata, psoriasis, and vitiligo; and may serve as a biological
marker of disease activity in patients with psoriasis and alopecia areata.
 2015 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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Prolactin (PRL) is a peptide hormone secreted by the
anterior pituitary gland and also by many extra-pituitary
sites, including immune cells (Jara et al., 2009). PRL has
a role in reproduction, calcium metabolism, osmoregula-
tion, and behavior (Jara et al., 2009; De Bellis et al.,
2005). The relationship between PRL and the immunehttp://dx.doi.org/10.1016/j.jdds.2015.03.002
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(De Bellis et al., 2005). PRL has multiple immune-stimula-
tory eﬀects and promotes autoimmunity. It increases the
synthesis of IFN-gamma and IL-2 by Th1 lymphocytes
(De Bellis et al., 2005). Moreover, PRL activates Th2
lymphocytes with autoantibody production (De Bellis
et al., 2005). Many studies evaluated the clinical signiﬁ-
cance of PRL in diﬀerent skin diseases with conﬂicting
results (Foitzik et al., 2009).2. Aim of the study
The aim of the present study was to evaluate the preva-
lence and clinical signiﬁcance of serum PRL levels in alope-
cia areata, vitiligo and psoriasis vulgaris patients and to
compare them with healthy controls.behalf of King Saud University.
commons.org/licenses/by-nc-nd/4.0/).
Table 2
Serum prolactin in patients and control subjects.
Subjects Psoriasis Alopecia Vitiligo Control
Serum PRL 16.9 ± 7 21.8 ± 12 16.6 ± 8 11.2 ± 6
P value .003 .000 .005
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This comparative, descriptive, case–control study
was conducted at the Dermatology department at
El-Jumhuriya Hospital, Benghazi city, Libya. A hundred
subjects were included in the study: 75 patients; suﬀering
from psoriasis, vitiligo and alopecia areata 25 patients in
each group and 25 age and gender-matched healthy con-
trols. A verbal consent was obtained from all patients
and healthy subjects after explaining the nature of the
study to them.
Exclusion criteria were presence of other autoimmune
diseases and use of drugs that are known to aﬀect levels
of PRL (i.e., psychotropic drugs, thyroid hormones, gluco-
corticoids, and estrogens or contraceptives). Pregnant and
lactating females were also not included in the study. All
patients who were on either topical or systemic treatment
for one month prior to blood collection were excluded
from the study. Blood was collected from all subjects and
serum PRL was measured by ELISA.
Psoriasis was graded according to the PASI score, pre-
senting at the time of blood collection. The patients were
divided into three groups based on the severity of the dis-
ease as mild (PASI <3), moderate (PASI 3.1-10) and severe
(PASI >10). Vitiligo patients were divided into two groups
as active and stable disease according to the progression of
the lesions and the appearance of new lesions in the last
three months. The activity of the disease among patients
with alopecia areata was determined by positive pull test
at the time of examination and/or progression of the
lesions in the last month. Comparative analyses were car-
ried out between age, gender, disease durations and activity
and serum PRL levels.
3.1. Statistical analysis
All statistical analyses were performed using SPSS soft-
ware for Windows (Version 16.0). Results are presented as
mean and standard deviations for continuous variables and
as a number (%) for categorical variables. Comparisons
between the patients and the control group were done by
t test. P values <0.05 were considered signiﬁcant.
4. Results
Table 1 shows the demographic characteristics of
patients and controls. No signiﬁcant diﬀerence between
patients and control subjects was noted.Table 1
Demographic data of patients under study and control subjects.
Subjects’ number Psoriasis 25 Alopecia 25
Age ± SD 35.8 ± 11 years 31 ± 6 years
Gender
Females 12 13
Males 13 12The mean serum PRL of psoriasis patients was
16.9 ± 6.8 ng/ml which is statistically signiﬁcantly higher
than serum PRL of control subjects (Table 2). No statisti-
cally signiﬁcant diﬀerence was found in serum PRL and
patient’s age or gender. Ten (66.7%) of the patients with
severe psoriasis and 1 (10%) patient with moderate psoria-
sis had high serum prolactin (P < 0.05). About 64% of the
patients had disease duration more than 5 years, and as the
disease duration increased, serum PRL level also increased
(P < 0.05).
Patients with vitiligo had a mean serum PRL of
16.6 ± 8 ng/ml which was signiﬁcantly higher than the
serum PRL of the control subjects (Table 2). No signiﬁcant
diﬀerence was found in patient’s serum PRL and their age,
gender, and disease durations. Regarding the activity of
their disease 12 (48%) of the patients had active disease,
and only 4 (36.4%) of the patients with active disease had
high serum PRL (P > 0.05).
Among patients with alopecia areata, 9 (36%) patients
had multiple patches of alopecia, 5 (20%) had alopecia
totalis and 11 (44%) of the patients had alopecia univer-
salis. Their mean serum PRL was 21.8 ± 11.5 ng/ml which
was signiﬁcantly higher than the serum PRL of the control
subjects (Table 2). No signiﬁcant diﬀerence was found in
patient’s serum PRL with their ages, gender and disease
duration, however there was a signiﬁcant correlation
between the type of alopecia and serum PRL (P < 0.05).
Regarding the activity of their disease 48% of the
patients had active disease, moreover 75% of the patients
with active disease had high serum PRL (P < 0.05). The
serum PRL was higher in patients with alopecia areata
compared with that in patients with psoriasis and vitiligo
but this diﬀerence was not statistically signiﬁcant.5. Discussion
Despite being known primarily as a lactogenic hormone,
PRL is in fact also an immunomodulatory hormone (Jara
et al., 2009). The relationship between PRL and the
immune system has been demonstrated in the last two dec-
ades and has opened new windows in the ﬁeld ofVitiligo 25 Control subjects 25 P value
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currently available prolactin-lowering drugs, bromocrip-
tine at least has been shown to decrease both peripheral
and pituitary PRL production and may represent a useful
adjunctive therapy in certain patients, particularly those
with refractory disease (Chuang and Molitch, 2007).
At present, the best evidence of a relationship between
PRL levels and disease activity exists for SLE, RA,
Reiter’s syndrome, and psoriasis (Chuang and Molitch,
2007). However, there are scarce reports in the literature
regarding the signiﬁcance of PRL in alopecia areata and
vitiligo (Go¨nu¨l, 2009; Go¨nu¨l et al., 2009).
Although many studies found increased serum PRL in
patients with psoriasis (Giasuddin et al., 1998; Dilme´-
Carreras et al., 2011), there is controversy, however, as to
whether raised PRL levels are associated with disease activ-
ity. Gorpelioglu et al. and Priestley et al. did not ﬁnd any
association between serum PRL levels and psoriasis as well
as its activity (Gorpelioglu et al., 2008; Priestley et al.,
1984). In contrast, a number of investigators have found
a signiﬁcant association between serum PRL and disease
activity (Giasuddin et al., 1998; Dilme´-Carreras et al.,
2011; Sanch, 2000).
Although hyperprolactinemia due to prolactinoma has
been reported in severe cases of psoriasis and treatment
with bromocriptine led to normalization of PRL levels
and concurrent improvement of their psoriatic lesions
(Sanch, 2000), none of our patients showed high serum
PRL in the range of prolactinoma.
Psoriasis is a T-cell-mediated autoimmune skin disease
characterized by hyperproliferation, abnormal diﬀerentia-
tion of keratinocytes, presence of inﬂammatory cell inﬁl-
trate and alterations to the dermal capillaries
(Gorpelioglu et al., 2008).
Several mediators and hormones have been implicated
in keratinocyte hyperproliferation. Among these hor-
mones, prolactin has been found to have a proliferative
eﬀect on epithelial cells, lymphocytes and keratinocytes in
in vitro studies. Moreover, normal PRL levels are required
for functions of immunocompetent T and B lymphocytes
(Girolomoni et al., 1993).
A signiﬁcantly elevated PRL level has been observed in
the psoriatic plaques’ lesions (El-Khateeb et al., 2011).
Moreover functional PRL receptors are detected on epider-
mal keratinocytes, indicating that PRL may be involved in
the hyperproliferation of keratinocytes in psoriasis (El-
Khateeb et al., 2011).
A previous study of serum PRL in patients with alope-
cia areata reported no signiﬁcant diﬀerence in serum PRL
levels and in the number of hyperprolactinemic individu-
als between the patient and control groups and they sug-
gested that prolactin does not play a role in the
pathogenesis of alopecia areata (Go¨nu¨l, 2009). In the pre-
sent study, serum PRL of alopecia areata patients was sig-
niﬁcantly higher than that of the control subjects.
Moreover there was a signiﬁcant correlation between the
type of alopecia and disease activity and the serumPRL. Alopecia areata has been considered to be an
autoimmune in origin. IFN-c is the main cytokine known
to be aberrantly expressed in alopecia areata through Th1
mediated response. It has been shown that serum levels of
IFN-c are signiﬁcantly higher in patients with alopecia
totalis or alopecia universalis compared to those in con-
trols, but no signiﬁcant diﬀerence has been found in the
levels of IFN-c between patients with localized alopecia
areata and those with more extensive forms (Arca et al.,
2004). PRL has multiple immunostimulatory eﬀects and
promotes autoimmunity. It increases the synthesis of
IFN-gamma and IL-2 by Th1 lymphocytes; moreover,
PRL activates Th2 lymphocytes with autoantibody pro-
duction (De Bellis et al., 2005).
Human skin, and and particularly scalp hair follicles,
are both direct extramammary targets and extrapituitary
sources of PRL (Foitzik et al., 2006). The catagen-inducing
eﬀects of PRL on human hair growth may help explain the
telogen eﬄuvium seen in patients with hyperprolactinemia
(Foitzik et al., 2009). PRL has been suggested to act as an
autocrine hair growth modulator with catagen promoting
functions and may serve as a hair growth-inhibitory hor-
mone (Foitzik et al., 2009).
There are scarce reports in the literature regarding the
signiﬁcance of PRL in patients with vitiligo. Recently, a
study evaluated the signiﬁcance of PRL in vitiligo and con-
cluded that PRL does not play a role in the pathogenesis of
vitiligo (Go¨nu¨l et al., 2009). However, serum PRL levels
among our patients with vitiligo were signiﬁcantly higher
than those of the control subjects, with no signiﬁcant asso-
ciation with disease activity or durations.
PRL has multiple immunostimulatory eﬀects and pro-
motes autoimmunity (De Bellis et al., 2005). PRL
increases the synthesis of IL-6 and IL-2 which are pro-
inﬂammatory cytokines that play an important role in
melanocytic cytotoxicity in vitiligo patients (Singh
et al., 2012). Many workers reported high IL-6 levels
in vitiligo patients. Il-6 was produced by mononuclear
cells, which could induce the expression of ICAM-1
(intercellular cell adhesion molecules) on melanocytes,
which might then facilitate leukocyte–melanocyte interac-
tions, leading to polyclonal B-cell activation subsequently
increasing autoantibody production, leading to immuno-
logical damage of melanocytes (Kirnbauer et al., 1992).
Moreover, PRL activates Th2 lymphocytes with autoan-
tibody production and enhances immunoglobulin pro-
duction which may contribute to increased
autoreactivity (De Bellis et al., 2005).6. Conclusions
The ﬁndings of increased prolactin levels in patients
with psoriasis, vitiligo and alopecia areata lead to the
assumption that prolactin may play a role in the pathogen-
esis of these diseases; moreover PRL may serve as a biolog-
ical marker for disease severity and activity.
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